Introduction: The NIAID biodefense research agendas for category A-C agents have identified a need for abroader, more robust arsenal of anti-infective agents. This is important when considered in the light ofrecent research in genomics and immunology which has greatly eased the task of genetic manipulation ofpathogens. Thus, Project II.A.2 arises from the lack of knowledge of key aspects of physiology of CategoryA-C pathogens which is fundamental to product development. In this project we will concentrate on: 1) Acomparison of isopentenyl diphosphate biosynthetic enzymes from a variety of pathogens with the ultimateaim of developing assays for high throughput screening in order to identify compounds that have potential fordevelopment into novel therapeutics. 2) the basic biology of cell wall synthesis in Bacillus anthacis, withemphasis on identifying anionic polysaccharides and the 'linker-unit' of the organism, polysaccharidebiosynthetic pathways and specific drug target identification.Project interactions: This project will be closely integrated with the other projects and Core Facilitiesdescribed in this proposal. The Project Leaders of this project (II.A.2) are Drs. Dean Crick and PatrickBrennan. Core III.C (Slayden) will provide HTS screening facilities, access to compound libraries andmicroarrays. Core III.D (Robison) will provide bacterial strains for testing with 'hit compounds'. We willinteract with Project II.C (Vasil) to test efficacy of compounds in intracellular models and Project II A3(Belisle) to test compound efficacy against Francisella tularensis. There will also be close interactions withProject II.A.4 (Schweizer). Our approach of looking for new antibiotic classes will synergize withSchweizers's search for compounds which inhibit efflux pumps. Thus, our hits can be tested for'pumpability' and synergy with compounds that inhibit efflux pumps.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI065357-04
Application #
7641021
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2008-05-01
Project End
2009-04-30
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$238,746
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Type
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418
York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167
Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167
Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:

Showing the most recent 10 out of 258 publications